<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Restoration of sinus rhythm in atrial flutter</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Restoration of sinus rhythm in atrial flutter</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Restoration of sinus rhythm in atrial flutter</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan M Prutkin, MD, MHA, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrial flutter is a supraventricular arrhythmia that can cause bothersome symptoms and promote atrial thrombus formation with the potential for systemic embolization. Restoration of sinus rhythm improves symptoms and decreases the risk of embolization if recurrence does not occur. (See  <a class="medical medical_review" href="/z/d/html/1048.html" rel="external">"Overview of atrial flutter", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/1066.html" rel="external">"Embolic risk and the role of anticoagulation in atrial flutter", section on 'Embolic risk'</a>.)</p><p>Issues related to the indications and therapeutic options for the restoration of sinus rhythm in atrial flutter will be reviewed here. Causes of atrial flutter, rate control therapy, the maintenance of sinus rhythm after cardioversion, and the role of anticoagulation in atrial flutter are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1067.html" rel="external">"Control of ventricular rate in atrial flutter"</a> and  <a class="medical medical_review" href="/z/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm"</a> and  <a class="medical medical_review" href="/z/d/html/1066.html" rel="external">"Embolic risk and the role of anticoagulation in atrial flutter"</a>.)</p><p class="headingAnchor" id="H88528146"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>Atrial flutter is a relatively common supraventricular arrhythmia that is characterized by rapid, regular atrial depolarizations at a characteristic rate of approximately 300 beats/min. (See  <a class="medical medical_review" href="/z/d/html/2118.html" rel="external">"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias", section on 'Atrial fibrillation and atrial flutter'</a> and  <a class="medical medical_review" href="/z/d/html/1048.html" rel="external">"Overview of atrial flutter"</a>.) </p><p>In the absence of rate slowing drugs or atrioventricular (AV) nodal disease, most commonly, every other beat is conducted through the AV node so that the ventricular rate is usually around 150 beats per minute. Because of the rapid rate, the patient may present with symptoms of palpitations, chest pain, dyspnea, fatigue, dizziness, and rarely hemodynamic shock, similar to patients with atrial fibrillation (AF) with a rapid ventricular response. (See  <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm", section on 'Adverse hemodynamics in AF'</a>.)</p><p>In addition to improving symptoms, the restoration of sinus rhythm prevents the potential for the development of tachycardia-mediated cardiomyopathy and somewhat reduces the risk of systemic embolization. (See  <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy", section on 'Atrial fibrillation and atrial flutter'</a> and  <a class="medical medical_review" href="/z/d/html/1066.html" rel="external">"Embolic risk and the role of anticoagulation in atrial flutter", section on 'Embolic risk'</a>.) </p><p>Atrial flutter is often an electrically unstable rhythm, meaning that it frequently degenerates into the more disorganized atrial fibrillation (AF) or reverts to sinus rhythm within hours or days, though it can also be chronic. Spontaneous reversion to a sinus mechanism may occur after predisposing problems are improved, such as decompensated heart failure (HF) or the sequelae of cardiac surgery. </p><p>In patients who do not spontaneously convert to sinus rhythm, rate slowing with drugs may be considered a therapeutic option. The ventricular rate is frequently difficult to control, however, as most medications are ineffective for rate slowing and for many patients it is not worth attempting as a long-term alternative to rhythm control. Rate control may be appropriate for patients who are reluctant to undergo cardioversion or who have no or minimal symptoms. (See  <a class="medical medical_review" href="/z/d/html/1067.html" rel="external">"Control of ventricular rate in atrial flutter"</a>.)</p><p>For those patients in whom a decision has been made to restore sinus rhythm, most can be cardioverted successfully without complication. Factors that predict spontaneous reversion to sinus rhythm or a successful cardioversion are similar to those for AF, and include a left atrial size less than 4.5 to 5 cm, little or no heart failure or left ventricular dysfunction, no underlying reversible cause such as hyperthyroidism, myocardial infarction, or pulmonary embolism, and atrial flutter of recent onset. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Reasons not to perform cardioversion'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Most patients with atrial flutter who do not undergo spontaneous conversion to sinus rhythm should undergo cardioversion. The following are indications for urgent cardioversion:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with atrial flutter who have a rapid ventricular rate and significant hemodynamic compromise (hypotension or heart failure) should undergo urgent cardioversion. In patients with atrial flutter and hemodynamic compromise, but with a controlled ventricular rate (eg, ≤100 beats/min), explanations for hemodynamic instability other than the atrial flutter should be sought. Restoration of sinus rhythm in these patients may not necessarily improve the clinical status. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with atrial flutter who are identified as having an accessory pathway with ventricular preexcitation should undergo immediate cardioversion. (See  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis", section on 'Atrial flutter'</a>.) </p><p></p><p>For patients with minimal symptoms or signs attributable to atrial flutter, conversion to sinus rhythm may be deferred in anticipation of either spontaneous conversion or radiofrequency catheter ablation. (See <a class="local">'Radiofrequency catheter ablation'</a> below.) </p><p>Among those patients who are not urgently cardioverted and who do not spontaneously revert to sinus rhythm, elective restoration of sinus rhythm is favored to decrease the risk of tachycardia-mediated cardiomyopathy. (See <a class="local">'Rationale'</a> above.) This is in contrast to atrial fibrillation (AF), in which tolerance of permanent AF may be more likely chosen since rate control is usually possible. (See  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a> and  <a class="medical medical_review" href="/z/d/html/1067.html" rel="external">"Control of ventricular rate in atrial flutter", section on 'Summary and recommendations'</a>.)</p><p>Circumstances in which it is reasonable to avoid cardioversion in patients with new onset atrial flutter include: </p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are completely asymptomatic, particularly those who are elderly with multiple comorbidities or poor overall prognosis, where the risks of undergoing cardioversion and/or pharmacologic rhythm control may outweigh the benefits of restoring sinus rhythm. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have a bleeding risk and cannot be anticoagulated during the peri-cardioversion and post-cardioversion periods. </p><p></p><p class="headingAnchor" id="H2682662"><span class="h1">METHOD OF CARDIOVERSION</span><span class="headingEndMark"> — </span>For most patients in whom a decision is made to restore sinus rhythm urgently, we prefer electrical to pharmacologic cardioversion. Radiofrequency catheter ablation is an option for stable patients who can wait until this procedure can be performed.</p><p class="headingAnchor" id="H3"><span class="h2">Electrical Cardioversion</span><span class="headingEndMark"> — </span>Electrical cardioversion, also called direct current (DC) cardioversion, is a routine procedure in the management of patients with cardiac arrhythmias and is the preferred means for the immediate restoration of sinus rhythm. With appropriate patient selection and technique, DC cardioversion is rapid and safe. The success rate of 96 to 97 percent is higher than for any antiarrhythmic drug [<a href="#rid1">1,2</a>]. (See <a class="local">'Pharmacologic cardioversion'</a> below.) </p><p>Electrical cardioversion should be performed by physicians experienced in the procedure. The patient should be fasting to allow for safe use of sedation, serum electrolytes should be normal, and drug levels, such as <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, should be within the therapeutic range. Cardioversion techniques are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation"</a>.)</p><p>It is expected that normal sinus rhythm will resume once the atrial flutter terminates. Sometimes, atrial fibrillation, ectopic atrial rhythm, or a significant bradycardia may result. The approach to each of these is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">"Temporary cardiac pacing"</a>.)</p><p class="headingAnchor" id="H28313518"><span class="h3">Pharmacologic enhancement of direct current cardioversion</span><span class="headingEndMark"> — </span>We use pharmacologic enhancement in selected patients. While the success of DC cardioversion is high for atrial flutter, antiarrhythmic drugs may be initiated prior to electrical cardioversion to increase the likelihood of successful cardioversion and long-term maintenance of sinus rhythm [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Preprocedural antiarrhythmic drugs'</a>.) </p><p>The decision to pretreat is often made by a physician experienced with the care of patients with one or more risk factors for cardioversion failure. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Reasons not to perform cardioversion'</a>.) The antiarrhythmic drug may restore sinus rhythm prior to DC cardioversion in some cases or may help prevent recurrent episodes of atrial flutter early after cardioversion. In addition, for patients in whom long-term antiarrhythmic therapy will be used, early initiation (prior to DC cardioversion) may allow for an evaluation of tolerability of one or more drugs. For those patients in whom a decision has been made to attempt the long-term maintenance of sinus rhythm with antiarrhythmic drug therapy, it is reasonable to preferentially select a drug for cardioversion that can also be used for long-term maintenance. Based on these considerations, we use pharmacologic enhancement in selected patients, such as those in whom ablation will not be performed. </p><p class="headingAnchor" id="H8"><span class="h2">Pharmacologic cardioversion</span><span class="headingEndMark"> — </span>A number of antiarrhythmic drugs may be used to terminate atrial flutter and restore sinus rhythm. However, antiarrhythmic drugs are less effective than DC cardioversion and carry some degree of proarrhythmic risk. Thus, pharmacologic cardioversion is generally reserved for selected clinical scenarios. The most common reason for selecting pharmacologic cardioversion is that moderate or deep sedation is either unavailable or is expected to be poorly tolerated (for example, as in patients with hypotension).</p><p>Most of the available data on the efficacy of antiarrhythmic drugs for the restoration of sinus rhythm are from patients with atrial fibrillation (AF). The drugs that are effective in converting AF to sinus rhythm may also be effective in converting atrial flutter. These include <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a>, and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. Ibutilide and dofetilide have been better studied than the other drugs discussed below. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Pharmacologic cardioversion'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> – Ibutilide, approved by the United States Food and Drug Administration for intravenous use, converts atrial flutter to sinus rhythm in approximately 60 percent of patients (compared to a 0 to 2 percent response to placebo) with a mean time to conversion of 30 minutes [<a href="#rid4">4-6</a>]. Ibutilide is more effective than <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> for reversion of atrial flutter (64 to 76 versus 0 to 14 percent) [<a href="#rid7">7,8</a>], and is also more effective than <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> (70 versus 19 percent)  (<a class="graphic graphic_figure graphicRef51703" href="/z/d/graphic/51703.html" rel="external">figure 1</a>) [<a href="#rid9">9</a>] and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> (87 versus 29 percent) [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/924.html" rel="external">"Therapeutic use of ibutilide"</a>.) </p><p></p><p class="bulletIndent1">The most serious concern with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> is QT interval prolongation that can lead to torsades de pointes [<a href="#rid4">4-6</a>]. The potential for torsades de pointes is increased in patients with severe heart failure or those who are being treated with another drug that prolongs the QT interval. On the other hand, the risk of proarrhythmia does not appear to be increased when ibutilide is given with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1">Because of the risk of torsades de pointes, patients treated with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> should be observed with continuous electrocardiogram (ECG) monitoring for at least four hours after the infusion. (See  <a class="medical medical_review" href="/z/d/html/924.html" rel="external">"Therapeutic use of ibutilide", section on 'Proarrhythmia'</a>.) The addition of intravenous magnesium, in doses of 4 to 10 grams, can enhance the cardioverting effect of ibutilide and may reduce the risk of torsades de pointes as well [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> – Oral dofetilide is effective for conversion of atrial flutter and the conversion rate appears to be higher than in AF. As an example, the SAFIRE-D study randomly assigned 325 patients with AF (n = 277) or atrial flutter (n = 48) to 125, 250, and 500 µg of dofetilide twice daily [<a href="#rid14">14</a>]. At a dose of 500 µg, the conversion rates for AF and atrial flutter were 22 and 67 percent, respectively, compared to 1.2 percent for placebo. Conversion to sinus rhythm occurred in 70 percent within 24 hours, while 91 percent converted within 36 hours. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> has the disadvantage of requiring the patient to be hospitalized for the first six doses, as it can cause torsade de pointes and sudden death [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1">Intravenous <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, which is not available in the United States, also appears to be effective for conversion of atrial flutter. In one study of 16 patients, 54 percent reverted to sinus rhythm after dofetilide administration while in another series of 17 patients the rate of reversion was 64 percent, compared with 0 percent for placebo [<a href="#rid17">17,18</a>]. Intravenous dofetilide is more effective than intravenous <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. In a randomized trial that included 31 patients with atrial flutter, the reversion rate with dofetilide was 75 percent versus 0 and 10 percent for amiodarone and placebo, respectively [<a href="#rid19">19</a>].</p><p></p><p>The following drugs are less commonly used or not recommended in this setting:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> – Intravenous (IV) amiodarone is sometimes used for atrial flutter conversion, but data are limited. A small study of nine patients with atrial flutter demonstrated no patients converting with IV amiodarone [<a href="#rid19">19</a>]. Another study of 21 patients showed a success rate of 29 percent with IV amiodarone compared to 87 percent for <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class IA antiarrhythmic drugs</strong> – The class IA antiarrhythmic drugs (<a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, and <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a>) slow the rate of contraction of the atria but also may have a significant vagolytic effect which increases atrioventricular (AV) nodal conduction. These combined actions can result in 1:1 conduction at very rapid ventricular rates  (<a class="graphic graphic_waveform graphicRef55441" href="/z/d/graphic/55441.html" rel="external">waveform 1</a>). For this reason, we do not recommend their use unless patients are pretreated with a drug(s) that blocks AV nodal conduction such as beta or calcium channel blockers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class IC antiarrhythmic drugs </strong>– The class IC antiarrhythmic drugs <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> and <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> are less efficacious than other agents. Although they do not accelerate AV conduction, they can slow the atrial flutter rate, often to a greater extent than the class IA drugs. Slowing of the atrial flutter rate alone (eg, to 200 or 250 beats/min) can lead to 1:1 AV conduction. We do not recommend their use unless patients are pretreated with a drug(s) that blocks AV nodal conduction such as beta or calcium channel blockers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rate control drugs</strong> – <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a>, nondihydropyridine calcium channel blockers [<a href="#rid20">20-22</a>], and beta blockers can all be effective in the control of the ventricular rate during atrial flutter. Although the hemodynamic improvement associated with a normalized ventricular rate may indirectly facilitate reversion to sinus rhythm, these drugs should be considered for the purpose of rate control, not for restoring sinus rhythm. (See  <a class="medical medical_review" href="/z/d/html/1067.html" rel="external">"Control of ventricular rate in atrial flutter"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">Vernakalant</a> – Intravenous vernakalant is approved by the European Commission for the rapid conversion of recent-onset atrial fibrillation (≤7 days duration for patients not undergoing surgery and ≤3 days duration for postcardiac surgery patients) to sinus rhythm. Based on one study in which the drug converted only 1 of 14 patients with atrial flutter, we do not recommend its use [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/895.html" rel="external">"Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs", section on 'Class III'</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Radiofrequency catheter ablation</span><span class="headingEndMark"> — </span>Radiofrequency catheter ablation (RFA) can be performed while a stable patient is in atrial flutter. In this setting, sinus rhythm is restored during the procedure. The use of RFA to interrupt the reentrant circuit supporting atrial flutter in order to <strong>permanently</strong> maintain normal sinus rhythm is discussed elsewhere [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm"</a>.) </p><p class="headingAnchor" id="H16"><span class="h2">Atrial overdrive pacing</span><span class="headingEndMark"> — </span>Atrial overdrive pacing may be used for cardioversion in selected patients with flutter, though it is rarely performed because of the high success rate of direct current cardioversion and/or ablation.</p><p>In atrial flutter, if the atrium is paced approximately 10 percent faster than the atrial flutter rate for 15 to 30 seconds, the rate of the tachycardia increases to match that of the faster pacing rate; that is, it is entrained [<a href="#rid26">26-28</a>]. </p><p>When the pacing is discontinued, one of several results may ensue:</p><p class="bulletIndent1"><span class="glyph">●</span>The original atrial flutter may return.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The atrial flutter may cease with restoration of normal sinus rhythm  (<a class="graphic graphic_waveform graphicRef56947" href="/z/d/graphic/56947.html" rel="external">waveform 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient may convert to AF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The atrial flutter may change, possibly at a faster rate [<a href="#rid29">29</a>].</p><p></p><p>Atrial pacing can be useful in selected patients, including the following [<a href="#rid26">26-28,30-32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>After cardiac surgery, since atrial pacing wires are often left in place during the early postoperative period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a pacemaker or implantable cardioverter-defibrillator where rapid pacing may be available through the device.</p><p></p><p>Very rarely, a temporary pacemaker may be used:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have recurrent atrial flutter due to an acute stress such as a myocardial infarction or respiratory failure; this represents a setting in which one would like to avoid repeated DC shocks and a temporary transvenous pacemaker can be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have digitalis toxicity, a condition in which DC cardioversion may be particularly dangerous. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients in whom anesthesia is a risk and pharmacologic cardioversion is not desired or unavailable [<a href="#rid26">26-28,33,34</a>].</p><p></p><p>The success rate of rapid atrial pacing may be increased by the concurrent intravenous administration of <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> or <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> [<a href="#rid35">35-37</a>]. </p><p class="headingAnchor" id="H88530058"><span class="h1">ANTICOAGULATION</span><span class="headingEndMark"> — </span>We agree with recommendations from the American Heart Association/American College of Cardiology/Heart Rhythm Society guideline on atrial fibrillation, which recommend that consideration be given to managing anticoagulation during cardioversion of atrial flutter in a manner similar to that for atrial fibrillation [<a href="#rid38">38-41</a>]. (See  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1066.html" rel="external">"Embolic risk and the role of anticoagulation in atrial flutter", section on 'Cardioversion'</a>.) </p><p class="headingAnchor" id="H2682610"><span class="h1">MAINTENANCE OF SINUS RHYTHM</span><span class="headingEndMark"> — </span>After conversion to sinus rhythm, an attempt should be made to address all correctable causes of atrial flutter (eg, thyrotoxicosis or obesity). (See  <a class="medical medical_review" href="/z/d/html/1048.html" rel="external">"Overview of atrial flutter", section on 'Etiology and risk factors'</a>.)</p><p>In addition to radiofrequency catheter ablation (see <a class="local">'Radiofrequency catheter ablation'</a> above), pharmacologic therapy can be used to maintain sinus rhythm. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm", section on 'Pharmacologic therapy'</a>.)</p><p class="headingAnchor" id="H240388585"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H25423249"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83438.html" rel="external">"Patient education: Atrial flutter (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamically unstable patient </strong>– For atrial flutter patients who have a rapid ventricular rate and evidence of hemodynamic instability or severe symptoms including myocardial ischemia, hypotension, angina, heart failure, or evidence of ventricular preexcitation, we recommend urgent electrical cardioversion rather than any other approach (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Indications'</a> above and <a class="local">'Electrical Cardioversion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable patient </strong>– For stable patients with atrial flutter, we suggest elective electrical cardioversion rather than pharmacologic cardioversion or atrial pacing in patients without atrial leads (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). </p><p></p><p class="bulletIndent1">Patients who may reasonably prefer other approaches such as an attempt at pharmacologic conversion (or at rate control) include those who prefer not to undergo electrical cardioversion or those for whom moderate or deep sedation will be poorly tolerated or not available. Radiofrequency catheter ablation, if performed in a timely manner, is a reasonable alternative to electrical cardioversion. (See <a class="local">'Indications'</a> above and <a class="local">'Electrical Cardioversion'</a> above.) </p><p></p><p class="bulletIndent1">Available data do not support the recommendation of a specific antiarrhythmic drug if pharmacologic conversion will be attempted. Options include <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, or <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>.</p><p></p><p class="bulletIndent1">We prefer <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> in situations where we desire acute pharmacologic cardioversion of atrial flutter. (See <a class="local">'Pharmacologic cardioversion'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for overdrive pacing </strong>– For patients with atrial pacing wires in place (either as part of a permanent pacemaker, implantable-cardioverter defibrillator, or temporary pacing wires after cardiac surgery), we suggest rapid atrial pacing rather than electrical cardioversion (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Atrial overdrive pacing'</a> above.)</p><p></p><p class="bulletIndent1">As rapid atrial pacing can cause atrial flutter to degenerate into atrial fibrillation (AF), the physician should be prepared for the management of AF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation </strong>– Anticoagulation during cardioversion of atrial flutter should be managed in a manner similar to that for atrial fibrillation. (See  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1066.html" rel="external">"Embolic risk and the role of anticoagulation in atrial flutter", section on 'Cardioversion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Method of rhythm control </strong>– In addition to radiofrequency catheter ablation, pharmacologic therapy can be used to maintain sinus rhythm. (See  <a class="medical medical_review" href="/z/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm", section on 'RF catheter ablation'</a> and  <a class="medical medical_review" href="/z/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm", section on 'Pharmacologic therapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001; 38:1498.</a></li><li><a class="nounderline abstract_t">Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68:41.</a></li><li><a class="nounderline abstract_t">Naccarelli GV, Dell'Orfano JT, Wolbrette DL, et al. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 2000; 85:36D.</a></li><li><a class="nounderline abstract_t">Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.</a></li><li><a class="nounderline abstract_t">Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28:130.</a></li><li><a class="nounderline abstract_t">Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998; 136:632.</a></li><li><a class="nounderline abstract_t">Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96:4298.</a></li><li><a class="nounderline abstract_t">Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31:1414.</a></li><li><a class="nounderline abstract_t">Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.</a></li><li><a class="nounderline abstract_t">Kafkas NV, Patsilinakos SP, Mertzanos GA, et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol 2007; 118:321.</a></li><li><a class="nounderline abstract_t">Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001; 103:253.</a></li><li><a class="nounderline abstract_t">Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106:673.</a></li><li><a class="nounderline abstract_t">Tercius AJ, Kluger J, Coleman CI, White CM. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol 2007; 30:1331.</a></li><li><a class="nounderline abstract_t">Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.</a></li><li><a class="nounderline abstract_t">Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation 2000; 102:2665.</a></li><li><a class="nounderline abstract_t">Abraham JM, Saliba WI, Vekstein C, et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015; 8:772.</a></li><li><a class="nounderline abstract_t">Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29:385.</a></li><li><a class="nounderline abstract_t">Nørgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999; 137:1062.</a></li><li><a class="nounderline abstract_t">Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000; 21:1265.</a></li><li><a class="nounderline abstract_t">Schamroth L, Krikler DM, Garrett C. Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J 1972; 1:660.</a></li><li><a class="nounderline abstract_t">Hagemeijer F. Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction. Circulation 1978; 57:751.</a></li><li><a class="nounderline abstract_t">Wolfson S, Herman MV, Sullivan JM, Gorlin R. Conversion of atrial fibrillation and flutter by propranolol. Br Heart J 1967; 29:305.</a></li><li><a class="nounderline abstract_t">Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010; 106:1277.</a></li><li><a class="nounderline abstract_t">Saoudi N, Atallah G, Kirkorian G, Touboul P. Catheter ablation of the atrial myocardium in human type I atrial flutter. Circulation 1990; 81:762.</a></li><li><a class="nounderline abstract_t">Da Costa A, Thévenin J, Roche F, et al. Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation 2006; 114:1676.</a></li><li><a class="nounderline abstract_t">Waldo AL, MacLean WA, Karp RB, et al. Entrainment and interruption of atrial flutter with atrial pacing: studies in man following open heart surgery. Circulation 1977; 56:737.</a></li><li class="breakAll">Waldo AL, Carlson MD, Biblo LA, Henthorn RW. The role of transient entrainment in atrial flutter. In: Atrial Arrhythmias: Current Concepts and Management, Tourboul P, Waldo AL (Eds), Mosby Year Book, St Louis 1990. p.210.</li><li><a class="nounderline abstract_t">Greenberg ML, Kelly TA, Lerman BB, DiMarco JP. Atrial pacing for conversion of atrial flutter. Am J Cardiol 1986; 58:95.</a></li><li><a class="nounderline abstract_t">Cheng J, Scheinman MM. Acceleration of typical atrial flutter due to double-wave reentry induced by programmed electrical stimulation. Circulation 1998; 97:1589.</a></li><li><a class="nounderline abstract_t">Peters RW, Shorofsky SR, Pelini M, et al. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J 1999; 137:100.</a></li><li><a class="nounderline abstract_t">Das G, Anand KM, Ankineedu K, et al. Atrial pacing for cardioversion of atrial flutter in digitalized patients. Am J Cardiol 1978; 41:308.</a></li><li><a class="nounderline abstract_t">Orlando J, Cassidy J, Aronow WS. High reversion of atrial flutter to sinus rhythm after atrial pacing in patients with pulmonary disease. Chest 1977; 71:580.</a></li><li><a class="nounderline abstract_t">Resnekov L. Cardiac arrhythmias. 6. Present status of electroversion in the management of cardiac dysrhythmias. Circulation 1973; 47:1356.</a></li><li><a class="nounderline abstract_t">Mann DL, Maisel AS, Atwood JE, et al. Absence of cardioversion-induced ventricular arrhythmias in patients with therapeutic digoxin levels. J Am Coll Cardiol 1985; 5:882.</a></li><li><a class="nounderline abstract_t">Cheng J, Glatter K, Yang Y, et al. Electrophysiological response of the right atrium to ibutilide during typical atrial flutter. Circulation 2002; 106:814.</a></li><li><a class="nounderline abstract_t">Olshansky B, Okumura K, Hess PG, et al. Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardiol 1988; 11:359.</a></li><li><a class="nounderline abstract_t">Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996; 77:960.</a></li><li><a class="nounderline abstract_t">You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</a></li><li><a class="nounderline abstract_t">Writing Group Members, January CT, Wann LS, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2019; 16:e66.</a></li></ol></div><div id="topicVersionRevision">Topic 1069 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11691530" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2058558" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10822039" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840852" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752805" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778066" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9416896" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9581743" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10078083" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17049640" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208685" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20723644" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976094" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11067793" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085972" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiovascular drugs. Dofetilide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063741" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9014993" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347332" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10924317" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5015294" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immediate effects of intravenous verapamil in cardiac arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/630684" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6023723" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Conversion of atrial fibrillation and flutter by propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21029824" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306828" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Catheter ablation of the atrial myocardium in human type I atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030680" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/912831" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Entrainment and interruption of atrial flutter with atrial pacing: studies in man following open heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/912831" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Entrainment and interruption of atrial flutter with atrial pacing: studies in man following open heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3728339" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Atrial pacing for conversion of atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593564" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acceleration of typical atrial flutter due to double-wave reentry induced by programmed electrical stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9878941" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/623021" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Atrial pacing for cardioversion of atrial flutter in digitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/856555" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High reversion of atrial flutter to sinus rhythm after atrial pacing in patients with pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4270092" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cardiac arrhythmias. 6. Present status of electroversion in the management of cardiac dysrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3973290" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Absence of cardioversion-induced ventricular arrhythmias in patients with therapeutic digoxin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176953" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Electrophysiological response of the right atrium to ibutilide during typical atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3339174" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644646" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315271" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682348" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30703530" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
